Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)

Recruiting now · Not applicable

Conditions studied: Cancer

In brief

The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).

Key facts

Study ID

NCT05558644

Run by

Institut Curie

People needed

50

Starts

2023-08-03

Expected to finish

2029-10-02

Last updated by the study team

2026-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient with suspicion of localised thymic epithelial tumour.
• Age ≥ 18 years.
• Treatment-naïve patient for this disease.
• Patient with an indication for thymectomy and thymomectomy in one of the partner centers.
• Signed informed consent form of the patient.

You may not qualify if…

• Neoadjuvant chemotherapy.
• No social security affiliation.
• Person under legal protection.
• Other neoplasia in progress or cured within the last 3 years (except for operated carcinoma in situ).

Where it is running

• Institut Curie Paris — Paris, France (enrolling)
• Institut Mutualiste Montsouris — Paris, France (enrolling)
• Hôpital FOCH — Suresnes, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.